- Home
- LXEH vs GDTC Comparison
LXEH vs GDTC Comparison
Compare LXEH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- GDTC
- Stock Information
- Founded
- LXEH 2001
- GDTC 2018
- Country
- LXEH China
- GDTC Singapore
- Employees
- LXEH N/A
- GDTC N/A
- Industry
- LXEH Other Consumer Services
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- GDTC Health Care
- Exchange
- LXEH Nasdaq
- GDTC Nasdaq
- Market Cap
- LXEH 25.1M
- GDTC 28.0M
- IPO Year
- LXEH 2020
- GDTC 2023
- Fundamental
- Price
- LXEH $1.37
- GDTC $2.30
- Analyst Decision
- LXEH
- GDTC Buy
- Analyst Count
- LXEH 0
- GDTC 1
- Target Price
- LXEH N/A
- GDTC $5.00
- AVG Volume (30 Days)
- LXEH 197.7K
- GDTC 7.3K
- Earning Date
- LXEH 04-30-2025
- GDTC 01-01-0001
- Dividend Yield
- LXEH N/A
- GDTC N/A
- EPS Growth
- LXEH N/A
- GDTC N/A
- EPS
- LXEH N/A
- GDTC N/A
- Revenue
- LXEH $4,493,795.00
- GDTC $368,838.00
- Revenue This Year
- LXEH N/A
- GDTC $5.37
- Revenue Next Year
- LXEH N/A
- GDTC N/A
- P/E Ratio
- LXEH N/A
- GDTC N/A
- Revenue Growth
- LXEH N/A
- GDTC N/A
- 52 Week Low
- LXEH $1.49
- GDTC $1.20
- 52 Week High
- LXEH $50.08
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- LXEH 33.37
- GDTC 54.58
- Support Level
- LXEH $1.49
- GDTC $2.25
- Resistance Level
- LXEH $1.85
- GDTC $2.35
- Average True Range (ATR)
- LXEH 0.15
- GDTC 0.08
- MACD
- LXEH 0.15
- GDTC 0.03
- Stochastic Oscillator
- LXEH 15.38
- GDTC 85.29
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.